How Does Particle Size Affect the Performance of Liposomal NAD+ Powder?

Why Particle Size Matters in Liposomal NAD+ Powder — and What "Performance" Means Here

Particle size is one of the few liposomal specifications every buyer can measure and quote, which is why it is so often over-interpreted. Throughout this article, performance means processing and system performance only: how a powder disperses on reconstitution, whether it cakes in storage, how a made-up suspension behaves, how quickly solids settle, and how consistently a filling line divides the material into equal portions. Performance here does not mean human absorption or any physiological effect, and a size number is not a proxy for either. A statement that a smaller measured diameter automatically produces greater uptake in a person lies outside what size data can support, and it is not a claim we make about liposomal NAD+ powder.

For NAD+ this clarification is not academic. The material is supplied from 10% up to 70% active, with the 50% grade most often requested, so the carrier-to-active ratio varies enormously across the family. The same average diameter can describe two powders whose processing behaviour has almost nothing in common. Reading a certificate of analysis without knowing the loading level behind it is the most common incoming-material review mistake.

The NAD+ Factor: An Unusually Wide Carrier-to-Active Ratio

The phospholipid carrier does two jobs at once: it forms the vesicle holding the active, and it supplies the bulk that makes the powder handleable. At 10% active the carrier is abundant and the material is lipid-dominated. At 60% or 70% the carrier is relatively scarce and the powder behaves more like a dense, hygroscopic active blend than a fluffy lipid powder. Particle size therefore is not one variable with one meaning: at low loading it is largely a flow and portioning variable, while at high loading it becomes far more sensitive to association between particles, and so to dispersion and settling. A window that is adequate for a 20% grade can be inadequate for a 70% grade, even when both carry the same Z-average target. Our guide to how liposomal NAD+ powder is manufactured shows where in the process those differences are introduced.

How Loading Level Changes What Particle Size Controls

The table below is a planning aid, not a substitute for your own trial data; final limits should be agreed against your internal control standard.

Loading level	Carrier-to-active balance	What size mainly governs	Dominant processing risk
10%–25%	Carrier-dominant	Flow, dusting, blend homogeneity, fill-weight uniformity	Uneven flow into small cavities; segregation in blends
30%–50% (50% common)	Intermediate	Wettability, suspension homogeneity, balance of dispersion and settling	Partial wetting and lumps, then slow sedimentation
60%–70%	Carrier-limited	Dispersion, particle association, settling rate	Aggregation, gel-like lumps, rapid settling or surface scum

Reading a DLS Report: Z-Average, PDI, Span and Distribution Weighting

Dynamic light scattering is the standard method for colloidal sizing, and the ISO framework for it is explicit about what the technique reports: an average hydrodynamic size plus a size distribution for sub-micrometre particles in a liquid. Two consequences follow. The value is hydrodynamic rather than geometric, and because the instrument measures scattered intensity, the result is weighted by scattering power rather than by mass or count.

Why one average is never enough

Intensity weighting rises steeply with diameter, so if even a small fraction of the sample forms large aggregates, the reported Z-average is pulled upward while most of the material sits in a much smaller population. A lot can therefore pass on Z-average and still hold an aggregate shoulder. Polydispersity index compresses distribution width into one figure, normally 0 to 1; values around 0.3 and below indicate a relatively narrow population, higher values a mixed or unstable one. PDI cannot tell those two cases apart on its own, which is why span and curve shape are read alongside it. The distribution basis matters equally: the same dataset can be presented as intensity-, volume- or number-weighted, and the three are not interchangeable. When two reports disagree, the first question is which basis each used. Our page on testing methods for liposomal NAD+ powder quality covers how the three bases are handled in release testing, and the companion analysis of how particle size affects liposomal vitamin C powder performance shows how differently the same metrics must be read for a water-soluble, lower-loading active.

Report field	What it describes	How to use it in acceptance
Z-average (nm)	Intensity-weighted mean hydrodynamic diameter of the whole population	Track as a lot-to-lot trend; never accept or reject on this alone
PDI	Width of the intensity distribution in one figure	Agree a ceiling (for example ≤0.30) and require multi-lot records
Span (D10/D50/D90)	Shape and tailing of the curve	Set a limit that catches a tail the Z-average conceals
Intensity / volume / number weighting	Three conversions of one dataset; intensity follows scattering power, number favours small particles	Require the basis to be stated; compare like with like only
Zeta potential (mV)	Surface charge and electrostatic repulsion between vesicles	Agree a range in your internal standard as a stability indicator
Sample preparation notes	Dilution medium, concentration, temperature, equilibration	Fix these in the specification; numbers taken under different conditions are not comparable

Particle Size and Encapsulation Efficiency Are Not Monotonically Linked

Encapsulation efficiency is specified at 85%–95%. It is tempting to assume a tighter or smaller distribution must push that figure higher, but the relationship is not monotonic. Very small vesicles have more curvature per unit of bilayer and a higher surface-to-volume ratio, and they can release retained material more readily during drying and handling; unusually narrow distributions can also flag an over-processed batch rather than a well-controlled one. Broad or bimodal distributions usually mean the process drifted and part of the material reassembled differently. Efficiency and size should therefore be specified together and judged together, never derived from one another. A recent review of encapsulation in formulated systems makes the broader version of this point: high encapsulation efficiency measured in isolation does not automatically translate into better behaviour in a real matrix. See our technical guide to improving liposomal NAD+ powder stability and the list of what should appear in a liposomal NAD+ powder certificate of analysis.

To set an acceptance interval, we recommend working in this order, with final limits recorded as agreed against your own internal control standard: fix the loading level first; collect DLS data from at least three consecutive lots to see the natural spread; set the Z-average window around that spread rather than a market figure; set PDI and span ceilings just wide enough to exclude drift you have actually observed; then confirm efficiency still lands inside 85%–95% across the same lots. A window that no supplier can hold is not a quality standard.

What Particle Size Data Cannot Tell You

A raw-material DLS report cannot do any of the following.

• It cannot predict absorption or systemic exposure in humans, which requires in vivo work on a finished formulation.
• It cannot replace stability data. Accelerated and real-time studies on your own matrix are the only evidence for how long the material holds up, which is why shelf-life questions belong with the factors that affect liposomal NAD+ powder shelf life.
• It cannot substitute for sensory and compatibility testing. Taste, mouthfeel, colour drift and interaction with other ingredients in your blend are observed, not calculated.
• It cannot distinguish genuine encapsulation from a simple lipid-and-active mixture; that needs complementary microscopy and an efficiency assay.
• It cannot be compared across suppliers unless preparation conditions, distribution basis and loading level are all stated.

Processing Essentials for High-Loading NAD+ Systems

At 50% and above the carrier has less slack, so discipline around the powder does more work than the size specification itself.

• Charge and pre-disperse under control. Add powder as a steady stream into liquid with agitation already running, rather than dumping it onto a dry vessel wall where it wets unevenly and forms persistent lumps. At the top of the range, a pre-blend with a compatible diluent helps.
• Do not over-shear. Excessive shear and long hold times can drive association and shift the distribution, so set a mixing energy and hold time and keep them.
• Manage moisture and hygroscopicity. The material is specified as free-flowing with no caking, and opened containers, humid filling rooms and exposed hold times work against that. Keep containers closed, work quickly, and monitor water content.
• Let the suspension rest before filling so entrained air leaves and the bulk reaches a stable state; this improves fill-weight consistency.
• Verify in line, not only in the warehouse. Turbidity or light-obscuration readings at the filling head catch a dispersion drift while the batch is still recoverable. Appearance is a useful first screen, and the visual conventions for these systems are described in what liposomal products actually look like. Screen incoming lots before they reach the line, following our guide to evaluating the purity and quality of liposomal NAD+ powder before buying.

Acceptance Checklist: Particle Size Items Plus the Mandatory Set

Size is necessary but never sufficient. Limits shown as examples must be confirmed against your own internal control standard and recorded in the supply agreement.

Item	Basis or target	When to check
Z-average	DLS, window agreed for your loading grade	Incoming and at each stability pull point
PDI	DLS, ceiling agreed (for example ≤0.30)	Incoming, across at least three lots
Span and tail	DLS, ceiling agreed; basis stated	Incoming, and on any out-of-trend lot
Morphology	Microscopy confirming bilayer structure	Qualification, and on process change
NAD+ content	HPLC, within the agreed range for the grade	Every lot
Encapsulation efficiency	85%–95%	Every lot, and through stability
Lead (Pb)	Below 0.1 ppm	Every lot, on the COA
Total plate count	Below 1,000 cfu/g	Every lot, on the COA
Appearance and flow	Pale yellow to white, free-flowing, no lumps	Receiving inspection
Re-dispersion	Cold water; stable colloidal suspension, no caking	Receiving, and after storage excursion
Documentation	COA, spec sheet, DLS report, microscopy, multi-lot data	Before supplier approval

Specification Snapshot

Parameter	Specification	Method
NAD+ content	10%–70% (50% grade commonly requested); raw material 99% purity	HPLC
Encapsulation efficiency	85%–95%	HPLC
Appearance	Pale yellow to white free-flowing fine powder	Visual
Dispersion	Highly water dispersible; stable colloidal suspension; no caking	Reconstitution
Particle size	Z-average, PDI and span reported per lot	DLS
Morphology	Bilayer structure confirmed	TEM
Shelf life	Up to 24 months	Stability protocol
Heavy metals (Pb)	Below 0.1 ppm	Elemental analysis
Total plate count	Below 1,000 cfu/g	Microbiological method
Certifications	cGMP, ISO 22000, ISO 9001, HALAL, KOSHER, Non-GMO, Vegan, Gluten-Free	Certificate review

Working With EmerWell

If you are qualifying NAD+ raw material at a specific loading level, the useful conversation is technical: which grade, which particle size window you intend to hold, and which distribution basis your QC system reports. We can share specifications, a representative certificate of analysis, DLS and microscopy documentation, stability information and samples, so your team can run its own dispersion and compatibility trials before any commitment. Tell us the loading level and the matrix you have in mind and we will confirm what we can support. Start from the liposomal NAD+ powder page, review selection criteria in our note on choosing a reliable liposomal NAD+ powder supplier, or email info@emerwell-bio.com with your specification requirements.

References

1. International Organization for Standardization. ISO 22412:2025, Particle size analysis — Dynamic light scattering (DLS). https://www.iso.org/standard/85505.html
2. Islam S, Nabi MHB, Ahmad I, Zzaman W. Encapsulation in Food Systems: From Technique-Driven Approaches to Functional, Scalable, and Sustainable Industrial Applications. International Journal of Food Science, 2026;2026:7367634. https://pmc.ncbi.nlm.nih.gov/articles/PMC13084698/
3. U.S. Food and Drug Administration. Dietary Supplements. https://www.fda.gov/food/dietary-supplements
4. International Council for Harmonisation. ICH Quality Guidelines (Q1 stability series). https://www.ich.org/page/quality-guidelines

Disclaimer: EmerWell supplies liposomal raw materials to manufacturers and does not provide medical advice. This article describes raw-material characterisation and processing parameters only. It is not a statement about the effects or suitability of any finished product, and nothing here should be read as a claim of health benefit. Specifications are agreed per lot and confirmed on the certificate of analysis.